Live Breaking News & Updates on Md University Heart Center Zurich|Page 1

Stay updated with breaking news from Md university heart center zurich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

DOAC Don'ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

There are scenarios when the agents may be harmful, and others where more evidence is urgently needed. ....

United States , Jan Steffel , Behnood Bikdeli , Antoine Bejjani , Md University Heart Center Zurich , European Heart Rhythm Association , American Heart Association , Journal Of The American College Cardiology , American College , University Heart Center Zurich , Heart Rhythm Association ,

EHRA Updates Its Popular 'Practical' NOAC Guide

April 29, 2021
The European Heart Rhythm Association (EHRA) has come out with the fourth iteration of its practical guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF), which has helped physicians deploy these medications since it first came out in 2013.
Senior author Hein Heidbüchel, MD, PhD (Antwerp University Hospital, Belgium), past president of EHRA, explained that the guide is meant to supplement and not supplant clinical practice guidelines. The comprehensive document covers everything from dosing and drug-drug interactions to use in high-risk patient groups, management of bleeding, and what to do when patients undergo various procedures. ....

Hein Heidb , Jan Steffel , European Heart Rhythm Association , Md University Heart Center Zurich , European Society Of Cardiology , Phd Antwerp University Hospital , Antwerp University Hospital , European Society , University Heart Center Zurich , ஐரோப்பிய இதயம் தாளம் சங்கம் , ம்ட் பல்கலைக்கழகம் இதயம் மையம் ஸுரி , ஐரோப்பிய சமூகம் ஆஃப் இருதயவியல் , ஆண்ட்வெர்ப் பல்கலைக்கழகம் மருத்துவமனை , ஐரோப்பிய சமூகம் , பல்கலைக்கழகம் இதயம் மையம் ஸுரி ,

Lower Dose of Edoxaban Supported in ENGAGE-AF-TIMI 48 Analysis

March 02, 2021
The lower dose of edoxaban (Savaysa; Daiichi-Sankyo) evaluated in ENGAGE AF-TIMI 48 provides a net clinical benefit, according to a new analysis of the trial, suggesting it may be useful for some patients with atrial fibrillation (AF).
The trial evaluated two doses of the direct oral anticoagulant (DOAC) versus warfarin 60 and 30 mg once daily; both could be cut in half in patients meeting certain criteria. The rate of a net clinical outcome incorporating stroke/systemic embolism, major bleeding, or death was significantly lower in patients who received the lower- versus higher-dose regimen (7.26% vs 8.01%; HR 0.90; 95% CI 0.84-0.98).
However, there was a trade-off with the lower dose it was associated with a greater risk of stroke/systemic embolism compared with the higher dose but with reduced risks of major, intracranial, GI, and life-threatening bleeding. ....

New York , United States , Comunidad Autonoma De Cataluna , Jonathan Halperin , Eman Rashed , Jan Steffel , Robert Giugliano , Elena Arbelo , Mount Sinai Medical Center , Md University Heart Center Zurich , Journal Of The American College Cardiology , Drug Administration , University Heart Center Zurich , Less Bleeding With Lower , American College , Universitat De Barcelona , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , காமுனிடட தன்னாட்சி டி கடலுள் , ஜொனாதன் ஹால்பெரின் , ஈமான் ராஷஎத் , ஏற்ற சினை மருத்துவ மையம் , ம்ட் பல்கலைக்கழகம் இதயம் மையம் ஸுரி , இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல் , பல்கலைக்கழகம் இதயம் மையம் ஸுரி , குறைவாக இரத்தப்போக்கு உடன் கீழ் ,